论文部分内容阅读
目的观察吉西他滨联合顺铂治疗非小细胞肺癌(NSCLC)的临床疗效。方法60例NSCLC初治患者,随机分为联合用药组(30例,吉西他滨联合顺铂治疗)和对照组(30例,单用吉西他滨治疗),所有患者在治疗2个周期结束后行胸部MSCT扫描及体表测量,至少有一个可测量病灶,目标病灶代表所累及的器官,用常规技术测量病灶直径≥20mm或螺旋CT测量直径≥10mm的的病灶;临床表浅病灶如可扪及淋巴结,超声检查作为体表可测量病灶,进行疗效评价。结果2组均无完全缓解,联合用药组临床受益率(以完全缓解+部分缓解+稳定计算)明显高于对照组(83.3%vs53.3%,P<0.05);进展率明显低于对照组(16.7%vs46.7%,P<0.05);不良反应率略高于对照组;2组均无毒性相关死亡病例。结论吉西他滨与顺铂联合化疗治疗NSCLC可取得较好疗效。
Objective To observe the clinical efficacy of gemcitabine and cisplatin in the treatment of non-small cell lung cancer (NSCLC). Methods Sixty patients with initial NSCLC were randomly divided into combined treatment group (30 cases, gemcitabine combined with cisplatin treatment) and control group (30 cases treated with gemcitabine alone), all patients underwent chest MSCT scanning at the end of 2 cycles And body surface measurement, there is at least one measurable lesion, the target lesion represents the involved organ, lesions of lesion diameter ≥20 mm or spiral CT diameter ≥10 mm are measured by conventional techniques; superficial clinical lesions such as palpable lymph nodes, Check as a measurable body surface lesions, the efficacy evaluation. The results of the two groups were not completely relieved, the clinical benefit rate of the combination group (complete remission + partial remission + stable calculation) was significantly higher than the control group (83.3% vs53.3%, P <0.05); the progress rate was significantly lower than the control group (16.7% vs46.7%, P <0.05). The rate of adverse reactions was slightly higher than that of the control group. No toxicity related deaths were found in the two groups. Conclusion Gemcitabine combined with cisplatin chemotherapy in NSCLC can achieve better results.